Claims for Patent: 9,198,966

Summary for Patent: 9,198,966

Title:	B-type plexin antagonists and uses thereof
Abstract:	The present invention concerns the field of cancer therapy. In particular, it relates to an antagonist of a B-type plexin which prevents the interaction of the B-type plexin with ErbB-2 for use as a medicament, in particular, for treating metastasizing cancer. The present invention also contemplates a method for identifying an antagonist which prevents the interaction of a B-type plexin with ErbB-2. Finally, the invention provides for a polynucleotide encoding a B-type plexin polypeptide which lacks a functional intracellular domain and the said polypeptide.
Inventor(s):	Offermanns; Stefan (Bad Nauheim, DE), Swiercz; Jakub (Bad Nauheim, DE), Worzfeld; Thomas (Bad Nauheim, DE)
Assignee:	Ruprecht-Karls-Universitat Heidelberg (Heidelberg, DE) Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. (Munich, DE)
Application Number:	13/983,715
Patent Claims:	1. A method for treating metastasizing cancer in a subject suffering therefrom comprising administering to the subject a therapeutically effective amount of an antagonist of a B-type plexin, wherein the antagonist prevents the interaction of the B-type plexin with ErbB-2. 2. The method of claim 1, wherein the metastasizing cancer is selected from the group consisting of breast cancer, ovarian cancer, stomach cancer, and uterine cancer. 3. The method of claim 1, wherein the antagonist is a nucleic acid that is capable of hybridizing specifically to the B-type plexin gene or to its transcripts and that prevents expression of the B-type plexin polypeptide. 4. The method of claim 3, wherein the nucleic acid is selected from the group consisting of an siRNA, a micro RNA, an antisense RNA, a morpholino oligonucleotides, a ribozymes, and a triple helix forming agents. 5. The method of claim 1, wherein the antagonist specifically binds to the B-type plexin polypeptide and inhibits binding of the B-type plexin polypeptide to Erb-B2. 6. The method of claim 5, wherein the antagonist binds to the extracellular domain of B-type plexin. 7. The method of claim 5, wherein the antagonist is selected from the group consisting of an antibody, an aptamer, a peptides, and a polypeptides. 8. The method of claim 1, wherein the antagonist is administered in combination with a cytotoxic compound, wherein the compound inhibits cell proliferation or differentiation of cancer cells, induces apoptosis of cancer cells, or prevents tumor angiogenesis. 9. The method of claim 1, wherein the compound is selected from the group consisting of trastuzumab, bevacizumab, tamoxifen, 5-fluorouracil, methotrexate, gemcitabine, Ara-C(Cytarabine), CCNU (Chloroethylcyclohexylnotrisourea), hydroxyurea, adriamycin, mitomycin C, mitoxantrone, doxorubicin, epirubicin, cisplatin, carboplatin, cyclophosphamide, ifosfamide, paclitaxel, docetaxel, vincristine, etoposide, irinotecan, and topotecan. 10. The method of claim 1, wherein the antagonist is a B-type plexin polypeptide that lacks a functional intracellular domain. 11. The method of claim 7, wherein the agonist is an antibody.

Details for Patent 9,198,966

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2031-02-09
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2031-02-09
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2031-02-09